ALK and neuroblastoma: The majority of reported ALK mutations in neuroblastoma are activating point mutations in the tyrosine kinase domain (TKD) that are present in 7–8% of all neuroblastoma cases, while amplification of the ALK locus occurs in approximately 2% of all sporadic neuroblastoma tumors.